D-1264-2019 Class II Ongoing

Recalled by Torrent Pharma Inc. — Basking Ridge, NJ

FDA drug recall D-1264-2019 was initiated by Torrent Pharma Inc. on Apr 18, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level. The recall status is ongoing. Affected quantity: 28,464 bottles.

Recall details

Product Type
Drugs
Report Date
May 8, 2019
Initiation Date
Apr 18, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
28,464 bottles

Product description

Losartan Potassium Tablets, USP, 25 mg, a) 90-count (NDC: 13668-113-90), b)1000-count (NDC: 13668-113-10) per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Count, lots, expiry: [90-count bottle] Lot BDK1C003, exp 07/31/2019; [1000-count bottle] Lot BDK1C002, exp 07/31/2019; Lots 4DU1D004, 4DU1D005, 4DU1D006, exp 12/31/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1264-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1264-2019. Report a data issue: hello@regdatalab.com.